Tanzania Advances Regulatory Reliance for Medicines: What TMDA's Marketing Authorisation Pathway Means for Industry

What's Changed?

Tanzania is strengthening the use of regulatory reliance as part of its approach to the marketing authorisation of human medicinal products.

On 30 June 2026, the Tanzania Medicines and Medical Devices Authority (TMDA) issued a public notice outlining its Regulatory Reliance Pathways for Marketing Authorisation of Human Medicinal Products. The notice was published by TMDA on 3 July 2026.

Regulatory reliance allows a national regulatory authority to consider and give significant weight to scientific assessments, regulatory decisions, or inspection outcomes conducted by another trusted regulatory authority.

According to TMDA, the approach is intended to reduce duplication, improve the efficiency of regulatory assessments, facilitate timely access to quality-assured medicines, and strengthen cooperation between regulatory authorities.

TMDA currently describes four major reliance-based evaluation pathways, applying a risk-based approach to the marketing authorisation of human medicinal products.

Why This Development Matters

Traditional regulatory review can require national authorities to repeat assessments that may already have been conducted by trusted reference regulators.

Reliance can help address this challenge by allowing TMDA to make use of existing scientific assessments and inspection outcomes while retaining responsibility for its own regulatory decision.

The objective is not simply to make registration faster. It is also to make better use of regulatory resources while maintaining appropriate oversight of medicines entering the Tanzanian market.

TMDA identifies several objectives for its reliance pathways, including:

• Reducing duplication of assessments and inspections

• Facilitating timely access to safe, effective and quality-assured medicines

• Supporting regulatory convergence with international standards

• Strengthening regulatory capacity

• Building cooperation and trust between regulatory authorities

For pharmaceutical companies seeking market access in Tanzania, understanding these pathways can therefore become an important part of regulatory planning.

Who Needs to Pay Attention?

This development is particularly relevant to:

✔ Pharmaceutical manufacturers

✔ Marketing authorisation applicants

✔ Regulatory affairs professionals

✔ Local representatives and applicants supporting product registration

✔ Companies expanding into the Tanzanian market

✔ Businesses pursuing market access across multiple African jurisdictions

Companies that already use reference-authority assessments or international regulatory pathways should assess how TMDA's reliance mechanisms may fit into their broader registration strategy.

What Companies Should Do Next

1. Understand the Available Reliance Pathways

Companies should identify which TMDA reliance pathway may be relevant to their product and regulatory history.

The appropriate route can depend on the reference authority, assessment already performed, product status, and supporting documentation available to the applicant.

2. Prepare Complete Supporting Documentation

Reliance does not eliminate the need for a strong regulatory submission.

Applicants should ensure that required assessment reports, inspection information, product documentation, and relevant authorisations are available and consistent with the product being submitted to TMDA.

3. Assess Product Consistency

Where a reliance pathway is based on an assessment conducted by another trusted authority, companies should carefully assess whether the product submitted to TMDA corresponds to the product covered by the reference assessment.

4. Monitor TMDA Updates

Regulatory reliance is an evolving area. Companies should continue monitoring TMDA publications, guidance, and procedural updates to understand how the pathways are being applied in practice.

ARQon Insight

Regulatory reliance is becoming one of the most important tools for improving regulatory efficiency worldwide.

For companies entering African markets, this means that regulatory strategy should no longer focus exclusively on individual national requirements.

Understanding which regulatory authorities are trusted, which assessments may be leveraged, and how reliance pathways operate can help companies develop more efficient regional market-access strategies.

Tanzania's approach demonstrates how national regulatory authorities can use international regulatory work while maintaining their own decision-making responsibilities.

For manufacturers, the opportunity is to incorporate reliance into regulatory planning before preparing market-entry submissions, not after.

Global Regulatory Trend

Tanzania's approach forms part of a wider global movement toward regulatory reliance, work-sharing and convergence.

The World Health Organisation promotes reliance as a way for regulatory authorities to optimise limited resources, avoid unnecessary duplication, and facilitate faster access to quality-assured medical products. TMDA's own framework similarly emphasises reducing duplicated assessments and inspections while strengthening regulatory capacity.

Across Africa, these approaches are particularly relevant as regulators work toward greater cooperation and harmonisation.

For companies planning regional expansion, this could gradually change the way regulatory submissions are prepared and sequenced across different African markets.

Key Takeaway

Tanzania's continued implementation of regulatory reliance pathways for human medicinal products represents an important development in the country's approach to marketing authorisation.

The latest TMDA public notice, issued 30 June 2026 and published 3 July 2026, reinforces the Authority's use of reliance as a mechanism to reduce regulatory duplication, improve efficiency, and support timely access to quality-assured medicines.

For pharmaceutical companies considering Tanzania, understanding these pathways can help inform regulatory strategy and potentially make the market-access process more efficient.

The broader message is clear: regulatory intelligence increasingly means understanding not only what a regulator requires, but also how regulators are changing the way they evaluate products.

How ARQon Can Support

ARQon supports healthcare and life sciences companies with:

• Regulatory intelligence and monitoring

• Tanzania market-entry strategy

• Pharmaceutical regulatory support

• Marketing authorisation planning

• Regulatory reliance assessment

• Cross-border regulatory strategy

• African market-access planning

  
  

Stay Ahead. Stay Compliant. Stay Informed.

With ARQon Regulatory Intelligence.